Loading…

β-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study

Abstract Background Results from preclinical and observational studies suggest that β-adrenoreceptor inhibition might influence disease progression of melanoma. Patients and methods Patients ⩾18 years with cutaneous melanoma (Breslow thickness >1 mm) registered in the Eindhoven Cancer Registry be...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2013-12, Vol.49 (18), p.3863-3871
Main Authors: Livingstone, E, Hollestein, L.M, van Herk-Sukel, M.P.P, van de Poll-Franse, L, Nijsten, T, Schadendorf, D, de Vries, E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Results from preclinical and observational studies suggest that β-adrenoreceptor inhibition might influence disease progression of melanoma. Patients and methods Patients ⩾18 years with cutaneous melanoma (Breslow thickness >1 mm) registered in the Eindhoven Cancer Registry between January 1, 1998 and December 31, 2010, who were also registered with PHARMO record linkage system (RLS), were eligible. Randomly selected patients using β-blockers from PHARMO record linkage system (RLS) matched on age and gender served as a control cohort. Adjusted time-dependent and time-fixed Cox proportional hazard models were employed to estimate the hazard ratio of all-cause mortality. Five-year relative survival rates for all-cause mortality were calculated to estimate disease specific survival. Results 203 of 709 eligible patients used β-blockers after melanoma diagnosis. The use of β-blockers was not associated with the risk of dying (adjusted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.55–1.24). Neither duration of exposure nor β-blocker dosage showed significant influence on survival. Five-year relative survival for β-blocker users was lower than in non-users amongst melanoma patients (80.9% and 83.7%, respectively) but higher among the β-blocker control group compared to the general population (101.4%). Conclusion Our results do not show a statistically significant impact of β-blocker exposure on overall survival of melanoma patients, regardless of the timing, duration or dosage of β-blocker use.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2013.07.141